1.88
-0.01(-0.53%)
Currency In USD
| Previous Close | 1.89 |
| Open | 1.89 |
| Day High | 1.92 |
| Day Low | 1.86 |
| 52-Week High | 8.89 |
| 52-Week Low | 1.86 |
| Volume | 181,044 |
| Average Volume | 1.03M |
| Market Cap | 188.61M |
| PE | -0.78 |
| EPS | -2.42 |
| Moving Average 50 Days | 3.18 |
| Moving Average 200 Days | 4.55 |
| Change | -0.01 |
If you invested $1000 in Acelyrin, Inc. (SLRN) since IPO date, it would be worth $104.44 as of February 05, 2025 at a share price of $1.88. Whereas If you bought $1000 worth of Acelyrin, Inc. (SLRN) shares 1 year ago, it would be worth $230.96 as of February 05, 2025 at a share price of $1.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
GlobeNewswire Inc.
Jan 06, 2025 9:00 PM GMT
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
GlobeNewswire Inc.
Jan 03, 2025 1:00 AM GMT
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a vir
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
GlobeNewswire Inc.
Dec 10, 2024 9:30 PM GMT
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in thyroid eye disease, with initiation of Phase 3 progra